Sage Therapeutics, Inc. (SAGE): Price and Financial Metrics
Today's Latest Price: $42.92 USD
Jul 10 4:00pm Add SAGE to Watchlist Sign Up POWR Components:
Buy & Hold Grade
Peer Grade Industry Rank SAGE Stock Summary SAGE's price/sales ratio is 256.45; that's higher than the P/S ratio of 98.43% of US stocks. Revenue growth over the past 12 months for Sage Therapeutics Inc comes in at -90.42%, a number that bests only 1.14% of the US stocks we're tracking. In terms of volatility of its share price, SAGE is more volatile than 96.27% of stocks we're observing. If you're looking for stocks that are quantitatively similar to Sage Therapeutics Inc, a group of peers worth examining would be GBT, RESN, FGEN, NVTA, and CUE. SAGE's SEC filings can be seen here. And to visit Sage Therapeutics Inc's official web site, go to www.sagerx.com. SAGE Price/Volume Stats
2.23B Sage Therapeutics, Inc. (SAGE) Company Bio
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.
SAGE Latest News Stream
All News Types Commentary Corp. News Cramer Earnings M&A New Coverage (Bearish) New Coverage (Bullish) Options Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Resumes Coverage (Bullish) Stock Offering Upgrade
Event/Time News Detail Loading, please wait... Latest SAGE News From Around the Web
Below are the latest news stories about Sage Therapeutics Inc that investors may wish to consider to help them evaluate SAGE as an investment opportunity.
Q1 2020 SAGE Therapeutics Inc Earnings Call
Biotech gets 7 drugs in partnership, 3 of which are in phase 2 testing Continue reading...
The following slide deck was published by Sage Therapeutics, Inc. in conjunction with this event....
The company, which failed pivotal clinical trials investigating major depression, aims to reverse its fortunes this year.
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 3:00 p.m. ET.
Read More 'SAGE' Stories Here
SAGE Price Returns
59.29% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.8328 seconds.